Advertisement

Topics

Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat

2014-08-27 03:18:47 | BioPortfolio

Summary

The beneficial effects on plasma lipids of Orlistat, a selective gastrointestinal lipase inhibitor, are largely independent of weight loss, and might include differential effects plasma non-esterified fatty acid (NEFA). Apart from their well-known effects on insulin resistance pathogenesis, elevated NEFA levels probably play also the most important role at peripheral levels in the pathogenesis of Growth Hormone (GH) insufficiency in obesity. Aim of this observational, mono-centre, randomized, simple-blind, cross-over study is to verify if the short-term treatment with Orlistat may results in decline in NEFA circulating levels when used in conjunction with low-fat diet and if this effect may restore the endogenous activity of GH/ Insulin-like growth factor (IGF)-1 axis, in the context of GH regulation of lipoprotein metabolism, thus adding a further benefit of Orlistat in obesity cross-linked neuroendocrine and metabolic dearrangement.

Description

Subjects:

Twenty obese postmenopausal women (age: 53.6±6.2; BMI: 34.1±4.0. Subjects were recruited, evaluated, and monitored at the Endocrinology Unit of the Department of Molecular and Clinical Endocrinology and Oncology. Before starting the study, all subjects underwent an initial screening assessment including a medical history, physical examination, laboratory parameters, and body weight.

Treatment protocol:

At study entry plasma samples were obtained for fasting plasma glucose, insulin, lipaemia (total, HDL and LDL cholesterol, tryglycerides), GH, IGF-1, and IGFBP-3. The subjects were randomized in two groups of treatment: 10 subjects received normo-caloric diet plus + orlistat (Xenical, Roche, UK) at a dose of 120 mg tid; 10 subjects received normo-caloric diet without the additional treatment. The duration of follow-up was 10 days for each treatment period, without any wash-out between the two periods. Each patient has been assigned to each group. Dynamic testing performed at the end of each period were the following: glucose, and insulin after an OGTT; GH after GHRH + arginine (GHRH+ARG); post-prandial lipaemia after a standard fat-rich meal. During the study period, the subjects maintained their usual pattern of physical activity. Subjects and investigators remained unaware of laboratory results until the end of the study.

Methods

At baseline and at the end of each period of treatment, the following parameters were also measured:

1. Anthropometric measurements, performed with the subjects wearing only underwear without shoes. Standing height was measured to the nearest cm using a wall-mounted stadiometer. Body weight was determined to the nearest 50 g using a calibrated balance beam scale. Body mass Index (BMI) was calculated as weight (kg) divided by height squared (m2) and used as an index for obesity. Measurements of the waist circumference, a measure of adipose tissue distribution and cardiovascular disease risk were taken at the mid-point between umbilicus and xiphoid.

2. Body composition was determined by conventional Bioelectrical Impedance Analysis (BIA) and by Impedance Vector Analysis (BIVA). Resistance (R) and reactance (Xc) were measured by a single investigator with a single-frequency 50 kHz bioelectrical impedance analyzer (BIA 101 RJL, Akern Bioresearch, Firenze, Italy) according to the standard tetrapolar technique. All evaluations were performed by the same operator blind in respect to subjects treatment.

3. Blood samples were obtained between 08:00 h and 09:00 h from antecubital vein after an overnight fast, with the patient in the resting position. Blood samples for hormonal determination were promptly centrifuged, and serum separated and stored at -20 C until assay. Blood glucose levels were determined by the glucose oxidase method immediately after the OGTT. The OGTT was performed using 75 g dextrose. Blood samples were obtained at 0, 30, 60, 90, 20, 150, and 180 minutes for plasma glucose and insulin measurements. The normal glycemic response to the OGTT was defined according to the criteria of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Total and HDL-cholesterol, and triglyceride concentrations were assayed in plasma by enzymatic colorimetric methods (Roche Molecular Biochemicals) on an autoanalyzer Cobas Mira (ABX Diagnostics). LDL-cholesterol was calculated using Friedewald formula. Changes in lipid profile was also analyzed by calculating the total/HDL cholesterol ratio. Plasma NEFA concentrations were analyzed by the enzymatic colorimetric method (Wako Chemicals). Serum insulin and c-peptide were measured by a solid-phase chemiluminescent enzyme immunoassay using commercially available kits (Immunolite Diagnostic Products Co, Los Angeles, CA, USA). The sensitivity of the assay were 0.1 and 0.3 ng/mL. The intra- and interassay coefficients of variations (CVs.) were 2.2 and 5.8%, respectively for insulin and 6.3 and 8.8%, respectively for c-peptide.

The GHRH (1-29, Geref, Serono, Rome, Italy)+ ARG (arginine hydrochloride, Salf, Bergamo, Italy) was performed. The GH response after ARG+GHRH was classified as deficient (GHD) when the GH peak was <4.2 µg/L and sufficient (GHS) when the GH peak was >4.2 µg/L. Serum GH levels were measured by immunoradiometric assay (IRMA) using commercially available kits (HGH-CTK-IRMA, Sorin, Saluggia, Italy). The sensitivity of the assay was 0.02 µg/L. The intra- and interassay coefficients of variations (CVs.) were 4.5 and 7.9%, respectively. Circulating IGF-I levels measured by IRMA after ethanol extraction using Diagnostic System Laboratories Inc. (Webster, Texas, USA). The normal ranges in 31-40, 41-50 and 51-60 yr old women were 100-390, 96-288, 90-250 µg/l, respectively. The sensitivity of the assay was 0.8 µg/l. The intra-assay CVs were 3.4, 3.0 and 1.5% for low, medium and high points of the standard curve, respectively. The inter-assay CVs were 8.2, 1.5 and 3.7% for low, medium and high points of the standard curve. For the purpose of this study, IGF-I levels were classified as normal when higher than -2 SD and deficient when it was lower than -2 SD. The IGFBP-3 assay had a sensitivity of 0•04 ng/l; the normal range for an adult female population of the same age range of our study population was 2.7-5.6 mg/L. The values for the molecular mass of IGF-I and IGFBP-3 used for the calculation were 7.649 kDa and 28.5 kDa, respectively.25 Post-prandial lipaemia was evaluated in the morning, after ≥ 12 h fasting, and over the 8 h following the standard meal (at 2, 4, 6 and 8) h. The standard meal consisted of a potato gateau (a pie made of mashed potato, whole milk, egg, cheese, ham and butter) which was consumed in 15-20 min. The meal, which provided 4090 kJ, was composed of 34% carbohydrates, 51% fat (34% saturated fat) and 15% protein.

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Conditions

Obesity

Intervention

Orlistat, normo-caloric diet

Status

Completed

Source

Federico II University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:18:47-0400

Clinical Trials [1738 Associated Clinical Trials listed on BioPortfolio]

A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss

This study compares two types of diet interventions: a low carbohydrate ketogenic diet (Atkins) and a low-fat diet combined with a medication (Orlistat).

Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults

This study will evaluate the efficacy of a multifactorial approach associated with orlistat (Xenical) in weight loss maintenance during 4 years. The effect of orlistat in combination with ...

RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity

This trial compares two treatment methods: 1. Orlistat 60 mg to be taken three times daily one capsule; indicated for weight loss in overweight adults. Important is also that it is...

A Study of Xenical (Orlistat) in Overweight and Obese Adolescents

This 2 arm study will assess the effect of Xenical on body mass index (BMI)in obese or overweight adolescents. Patients will be randomised into one of 2 groups; both groups will undergo a ...

Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes

This study is designed to address the hypothesis that in obese patients with type 2 diabetes mellitus (DM), a low carbohydrate diet not specifically restricted in calories compared to low ...

PubMed Articles [4653 Associated PubMed Articles listed on BioPortfolio]

Daily cycle in hepatic lipid metabolism in obese mice, Neotomodon alstoni: Sex differences.

Disruption of circadian rhythms influences the pathogenesis of obesity, particularly with the basic regulation of food intake and metabolism. A link between metabolism and the circadian clock is the p...

A new scope for orlistat: Effect of approved anti-obesity drug against experimental microsporidiosis.

As the current therapies for intestinal microsporidiosis are either inconsistent in their efficacies or hampered by several adverse effects, alternative antimicrosporidial agents are being sought. The...

TGF-β1 down-regulation in the mediobasal hypothalamus attenuates hypothalamic inflammation and protects against diet-induced obesity.

The consumption of large amounts of dietary fats induces hypothalamic inflammation and impairs the function of the melanocortin system, leading to a defective regulation of caloric intake and whole-bo...

Monetary diet cost is positively associated with diet quality and obesity: an analysis of school-aged children in Southwest China.

Little is known about the relationships between diet cost, dietary intake and obesity in Chinese populations. This study explored how diet cost was related to diet quality and obesity among school-age...

The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity.

Apigenin can exert beneficial actions in the prevention of obesity. However, its putative action on obesity-associated bowel motor dysfunctions is unknown. This study examined the effects of apigenin ...

Medical and Biotech [MESH] Definitions

A course of food intake that is high in FATS and low in CARBOHYDRATES. This diet provides sufficient PROTEINS for growth but insufficient amount of carbohydrates for the energy needs of the body. A ketogenic diet generates 80-90% of caloric requirements from fats and the remainder from proteins.

Reduction in caloric intake without reduction in adequate nutrition. In experimental animals, caloric restriction has been shown to extend lifespan and enhance other physiological variables.

A diet that contains limited amounts of CARBOHYDRATES. This is in distinction to a regular DIET.

Regular course of eating and drinking adopted by a person or animal. This does not include DIET THERAPY, a specific diet prescribed in the treatment of a disease.

Activities related to WEIGHT REDUCTION in patients with OBESITY. Treatment methods include DIET; EXERCISE; BEHAVIOR MODIFICATION; medications; and BARIATRIC SURGERY.

More From BioPortfolio on "Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Searches Linking to this Trial